Vobra Duo (B7-H3 ADC)

Background

Vobramitamab duocarmazine (or vobra duo, previously known as MGC018) is an investigational antibody-drug conjugate (ADC) comprised of a humanized B7-H3 monoclonal antibody (mAb) conjugated via a cleavable linker to the prodrug seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA; licensed from Byondis, B.V.), with an average drug-to-antibody ratio (DAR) of ~2.7. DUBA is an alkylating agent that can damage DNA in both dividing and non-dividing cells, causing cell death. Vobra duo is designed to target solid tumors expressing B7-H3.

Clinical Development

Please refer to our most recent corporate deck on our Events & Presentations page for the latest clinical information available on vobra duo.

Our Rights

MacroGenics retains global rights to vobra duo.

Clinical Trials

• Vobra Duo (MGC018) Phase 1 Study in Advanced Solid Tumors (NCT03729596)
• Vobra Duo (MGC018) in Combination with Lorigerlimab (MGD019) Phase 1 Study in Advanced Solid Tumors (NCT05293496)
• Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer (TAMARACK) (NCT05551117)
• IST: Phase 2 Study of MGC018 in Patients with Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer (NCT06227546)

Presentations & Publications

Relevant Publications and Presentations can be found at https://macrogenics.com/publications/.

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.